FDA Approves Updated Label for Unloxcyt

FDA Approves Myqorzo for Symptomatic Obstructive Hypertrophic Cardiomyopathy

drugs.com - 05/Jan 22:53

MONDAY, Jan. 5, 2026 -- The U.S. Food and Drug Administration has approved Myqorzo (aficamten) for the treatment of adults with symptomatic...

Breakthrough In Acute Pain Management: FDA Approves First-In-Class Non-Opioid

dailywire.com - 08/Jan 12:29

On Thursday, the U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic for...

Breakthrough In Acute Pain Management: FDA Approves First-In-Class Non-Opioid

dailywire.com - 08/Jan 12:29

On Thursday, the U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic for...

FDA Approves Zycubo (copper histidinate) for Children With Menkes Disease

drugs.com - 12/Jan 22:01

January 12, 2026 -- The U.S. Food and Drug Administration today approved the Zycubo (copper histidinate) injection as the first treatment for Menkes...

FDA Approves Zycubo (copper histidinate) for Children With Menkes Disease

drugs.com - 12/Jan 22:01

January 12, 2026 -- The U.S. Food and Drug Administration today approved the Zycubo (copper histidinate) injection as the first treatment for Menkes...

FDA Approves First Oral Drug for Thalassemia Anemia

medindia.net - 12/Jan 14:57

FDA approves Mitapivat, the first oral treatment for thalassemia anemia, helping reduce transfusion needs and raise hemoglobin levels in adults.

Camurus Announces FDA Acceptance of NDA Resubmission for Oclaiz for the Treatment of Acromegaly

drugs.com - 09/Jan 20:01

LUND, Sweden, Jan. 9, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted...

Camurus Announces FDA Acceptance of NDA Resubmission for Oclaiz for the Treatment of Acromegaly

drugs.com - 09/Jan 20:01

LUND, Sweden, Jan. 9, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted...

FDA Increases Flexibility on Requirements for Cell and Gene Therapies to Advance Innovation

mangaloremirror.com - 12/Jan 02:54

White Oak, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) — The U.S. Food and Drug Administration today announced it is sharing information about the...

FDA Increases Flexibility on Requirements for Cell and Gene Therapies to Advance Innovation

mangaloremirror.com - 12/Jan 02:54

White Oak, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) — The U.S. Food and Drug Administration today announced it is sharing information about the...

Rubriques :

FDA Approves Updated Label for Unloxcyt

Articles similaires

FDA Approves Myqorzo for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Breakthrough In Acute Pain Management: FDA Approves First-In-Class Non-Opioid

Breakthrough In Acute Pain Management: FDA Approves First-In-Class Non-Opioid

FDA Approves Zycubo (copper histidinate) for Children With Menkes Disease

FDA Approves Zycubo (copper histidinate) for Children With Menkes Disease

FDA Approves First Oral Drug for Thalassemia Anemia

Camurus Announces FDA Acceptance of NDA Resubmission for Oclaiz for the Treatment of Acromegaly

Camurus Announces FDA Acceptance of NDA Resubmission for Oclaiz for the Treatment of Acromegaly

FDA Increases Flexibility on Requirements for Cell and Gene Therapies to Advance Innovation

FDA Increases Flexibility on Requirements for Cell and Gene Therapies to Advance Innovation

Les derniers communiqués